1. Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. (October 2020) Authors: Kizilbash, S.H.; El-Khoueiry, A.; Lerner, R.E.; Ma, P.C.; Almubarak, M.; Mody, K.; Burkard, M.E.; Guarino, M.; Jenab-Wolcott, J.; Sankar, N.; Choy, G.; Espiritu, L.; Zhang, X.; Luria, A.; Benedetti, F.; Dees, E.C. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. (November 2017) Authors: Pilotto, S.; Carbognin, L.; Karachaliou, N.; Ma, P.C.; Rosell, R.; Tortora, G.; Bria, E. Journal: Cancer treatment reviews Issue: Volume 60(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗